Pacira BioSciences, Inc. (PCRX)
Quick ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Cash | US$ in thousands | 276,774 | 153,298 | 104,139 | 585,578 | 99,957 |
| Short-term investments | US$ in thousands | 207,841 | 125,283 | 184,512 | 70,831 | 421,705 |
| Receivables | US$ in thousands | — | — | — | — | — |
| Total current liabilities | US$ in thousands | 309,920 | 97,383 | 147,774 | 521,118 | 253,328 |
| Quick ratio | 1.56 | 2.86 | 1.95 | 1.26 | 2.06 |
December 31, 2024 calculation
Quick ratio = (Cash + Short-term investments + Receivables) ÷ Total current liabilities
= ($276,774K
+ $207,841K
+ $—K)
÷ $309,920K
= 1.56
The quick ratio of Pacira BioSciences, Inc. has shown fluctuations over the past five years. As of December 31, 2020, the quick ratio was 2.06, indicating a strong liquidity position with more than sufficient quick assets to cover current liabilities. However, by December 31, 2021, the quick ratio had decreased to 1.26, suggesting a potential decrease in the company's ability to meet its short-term obligations using only its most liquid assets.
The quick ratio improved in the subsequent years, reaching 1.95 by December 31, 2022, and further increasing to 2.86 by December 31, 2023, indicating a significant enhancement in liquidity and the company's ability to cover its short-term liabilities comfortably. However, by December 31, 2024, the quick ratio decreased to 1.56, reflecting a potential reduction in the company's ability to meet short-term obligations using only quick assets.
Overall, the quick ratio trend of Pacira BioSciences, Inc. shows variability in liquidity levels over the years, with periods of strong and weaker liquidity positions. It is essential for stakeholders to monitor these fluctuations and assess the company's ability to meet its short-term obligations effectively.
Peer comparison
Dec 31, 2024